Amgen at neutral by Merrill

Amgen Inc. was rated at neutral by Merrill Lynch analyst Eric Ende as the company opens up a second front in the legal battle with Roche over CERA, its pegylated-EPO product candidate, by filing a complaint with the International Trade Commission. Amgen had previously filed suit in federal court alleging that Roche's importation of materials to manufacture CERA constituted infringement of Amgen's EPO patent estate. Shares of the Thousand Oaks, Calif., biotechnology company were down $0.27, or 0.38%, at $69.97 on volume of 8,257,564 shares versus the three-month running average of 10,783,000 shares. (Nasdaq: AMGN)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.